Delonix Bioworks Begins Dosing Patients With Next-Gen MenB Vaccine in Australia
A Shanghai-based biotech is going global with an engineered MenB vaccine — and they're running the Phase 1 head-to-head against GSK's Bexsero.
Jeff Martin
Panacea Capital Forms Seismic Pharmaceuticals With Windtree’s Heart Failure Pipeline
Windtree sold its entire cardiovascular pipeline for pennies on the dollar. Now Panacea Capital is betting it can take istaroxime to Phase 3.
Aprea Therapeutics Reports Confirmed Response for WEE1 Inhibitor in Endometrial Cancer
Two confirmed partial responses, 50%+ tumor shrinkage, and a $30M oversubscribed raise. Aprea went from burning runway to suddenly very interesting.
Immusoft Lands $15M CIRM Grant to Advance Engineered B Cell Therapy for MPS I
Immusoft just scored its second CIRM grant — and its engineered B cells are doing something no other cell therapy has done: safe re-dosing.
Centivax Raises $37M to Chase Universal Flu Vaccine Into Phase 2
Merck paid $9.2 billion for Cidara's universal flu program. Now Centivax raises $37M — with the Stripe founders backing them — to push its own into Phase 2.
Aurinia Acquires Kezar Life Sciences in Kevin Tang’s Biotech Comeback Play
Kevin Tang tried to buy Kezar once and got rejected. Now he's back — as Aurinia's CEO — and this time he got the deal done.
Ollin Biosciences’ OLN324 Beats Roche’s Vabysmo in Head-to-Head Retinal Trial
A Phase 1b head-to-head study shows OLN324 outperforming Vabysmo in wet AMD and DME — and the CEO helped build the drug it just beat.
Stop Inhibiting. Start Destroying.
TRIANA Biomedicines doses the first patient with TRI-611, a brain-penetrant molecular glue degrader that eliminates ALK fusion proteins — not just blocks them.
$787 Million Says AI Can Design Better Biologics Than You
An AI-native biologics company just raised $787M with Sanofi and a Pfizer/Hillhouse fund backing it — and they already have a Phase 2 asset.
Teaching a Gene Editor to Optimize Itself
Specific Biologics just got government funding to build a machine learning layer on top of its Dualase gene editing platform — targeting repeat expansion diseases like ALS.